Clinical study of PD-1 disrupted anti-MUC1 CAR-T cells in patients with advanced oesophageal cancer

被引：3
|
作者：
Chen, S. [1 ]
Lin, Y. [2 ]
Cui, Y. [1 ]
Zhou, C. [3 ]
An, H. [3 ]
Huang, J. [1 ]
Su, Z. [1 ]
McGowan, E. [4 ]
机构：
[1] Guangdong Pharmaceut Univ, Affiliated Hosp 1, Guangdong Prov Engn Res Ctr Esophageal Canc Preci, Guangzhou, Peoples R China
[2] Univ Technol Sydney, Sch Life Sci, Sydney, NSW, Australia
[3] Guangzhou Anjie Biomed Technol Co Ltd, Guangzhou, Peoples R China
[4] Univ Technol Sydney, Ultimo, Australia
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.05.312
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-258
引用
收藏
页码：S186 / S186
页数：1
相关论文
共 50 条
  • [21] Anti-MUC1 antibody inhibits EGF receptor signaling in cancer cells
    Hisatsune, Akinori
    Nakayama, Hideki
    Kawasaki, Mitsuru
    Horie, Ichiro
    Miyata, Takeshi
    Isohama, Yoichiro
    Kim, Kwang Chul
    Katsuki, Hiroshi
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2011, 405 (03) : 377 - 381
  • [22] Chimeric antigen receptor T (CAR-T) cell therapy with intrinsic PD-1 blocking for ovarian cancer
    Ukita, Masayo
    Hamanishi, Junzo
    Murakami, Ryusuke
    Abiko, Kaoru
    Baba, Tsukasa
    Mandai, Masaki
    CANCER SCIENCE, 2018, 109 : 335 - 335
  • [23] A Systematic Review on PD-1 Blockade and PD-1 Gene-Editing of CAR-T Cells for Glioma Therapy: From Deciphering to Personalized Medicine
    Abdoli Shadbad, Mahdi
    Hemmat, Nima
    Khaze Shahgoli, Vahid
    Derakhshani, Afshin
    Baradaran, Farzad
    Brunetti, Oronzo
    Fasano, Rossella
    Bernardini, Renato
    Silvestris, Nicola
    Baradaran, Behzad
    FRONTIERS IN IMMUNOLOGY, 2022, 12
  • [24] Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors
    Zhenguang Wang
    Na Li
    Kaichao Feng
    Meixia Chen
    Yan Zhang
    Yang Liu
    Qingming Yang
    Jing Nie
    Na Tang
    Xingying Zhang
    Chen Cheng
    Lianjun Shen
    Jiaping He
    Xun Ye
    Wei Cao
    Haoyi Wang
    Weidong Han
    Cellular & Molecular Immunology, 2021, 18 : 2188 - 2198
  • [25] Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors
    Wang, Zhenguang
    Li, Na
    Feng, Kaichao
    Chen, Meixia
    Zhang, Yan
    Liu, Yang
    Yang, Qingming
    Nie, Jing
    Tang, Na
    Zhang, Xingying
    Cheng, Chen
    Shen, Lianjun
    He, Jiaping
    Ye, Xun
    Cao, Wei
    Wang, Haoyi
    Han, Weidong
    CELLULAR & MOLECULAR IMMUNOLOGY, 2021, 18 (09) : 2188 - 2198
  • [26] The efficacy and safety of PD-L1-specific CAR-T in advanced gastric cancer
    Park, Hye-Seong
    Choi, Eun-Ji
    Yu, Jae-In
    Lee, Kyung-Sik
    Lim, Yeo-Jin
    Choi, Se-Ryeong
    Choi, Yoonjoo
    Park, Bum Chan
    Park, Jae Eun
    Kim, Mihwa
    Lee, Je-Jung
    Rhee, Joon Haeng
    CANCER RESEARCH, 2023, 83 (07)
  • [27] Human anti-MUC1 antibodies elicited by a prophylactic cancer vaccine for mAb and CAR-modified T cell immunotherapies
    Lohmueller, Jason
    Finn, Olivera
    JOURNAL OF IMMUNOLOGY, 2014, 192
  • [28] Human anti-MUC1 antibodies elicited by a prophylactic cancer vaccine for mAb and CAR-modified T cell immunotherapies
    Lohmueller, Jason J.
    Sato, Shuji
    Cheung, Wan Cheung
    Chu, Isabel
    Popova, Lana
    Manning, Christopher A.
    Crosby, Katherine
    Grange, Christopher
    Ham, James D.
    Polakiewicz, Roberto D.
    Finn, Olivera J.
    CANCER RESEARCH, 2015, 75
  • [29] A VHH-Based Anti-MUC1 Chimeric Antigen Receptor for Specific Retargeting of Human Primary T Cells to MUC1-Positive Cancer Cells
    Rajabzadeh, Alireza
    Rahbarizadeh, Fatemeh
    Ahmadvand, Davoud
    Salmani, Maryam Kabir
    Hamidieh, Amir Ali
    CELL JOURNAL, 2021, 22 (04) : 502 - 513
  • [30] PEMBROLIZUMAB BLOCKS PD-1 ON CAR T CELLS ADMINISTERED INTRAVENTRICULARLY TO GLIOBLASTOMA PATIENTS
    Portnow, Jana
    Synold, Timothy
    Tran, Vivi
    Chiu, Vivian
    Alizadeh, Darya
    Wang, Dongrui
    Brito, Alfonso
    Kilpatrick, Julie
    Mcnamara, Paige
    Forman, Stephen
    Badie, Behnam
    Brown, Christine
    NEURO-ONCOLOGY, 2018, 20 : 4 - 4
12345